Laryngotracheobronchitis: 2 years' experience with racemic epinephrine

Area of Science:

• Pediatric Pulmonology
• Critical Care Medicine
• Respiratory Therapy

Background:

• Laryngotracheobronchitis (LTB) is a common pediatric respiratory illness.
• Tracheostomy and prolonged hospitalization were traditional management challenges for severe LTB.
• Racemic epinephrine via intermittent positive-pressure breathing (IPPB) emerged as a novel therapeutic approach.

Purpose of the Study:

• To evaluate the efficacy and safety of racemic epinephrine administered via IPPB for LTB treatment.
• To compare outcomes before and after the introduction of this new treatment modality.
• To assess the impact on tracheostomy rates and hospital length of stay.

Main Methods:

• Retrospective review of pediatric patients treated for LTB.
• Analysis of data from 2 years of IPPB racemic epinephrine use compared to 3 prior years.
• Tracking of tracheostomy rates, hospital duration, and treatment complications.

Main Results:

• A significant reduction in the necessity for tracheostomy, approaching zero.
• A notable decrease in the average duration of hospital stay for treated children.
• 119 children received treatment (33.15% of admissions), averaging 1.8 treatments.
• No significant complications or deaths were associated with the treatment.

Conclusions:

• IPPB administration of racemic epinephrine is a safe and effective treatment for pediatric laryngotracheobronchitis.
• This therapeutic strategy substantially decreases the need for tracheostomy and shortens hospital stays.
• The treatment offers a valuable, low-complication alternative for managing LTB in children.